Results 31 to 40 of about 5,922,427 (309)

Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy

open access: yesHaematologica
Not available.
Wolfgang Bethge   +2 more
doaj   +1 more source

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK

open access: yesBMC Cancer, 2022
Background The therapeutic armamentarium in multiple myeloma has been significantly broadened by proteasome inhibitors, highly efficient means in controlling of multiple myeloma.
Azam Salimi   +7 more
doaj   +1 more source

Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients [PDF]

open access: yes, 2013
Despite the availability of new antifungal compounds, invasive fungal infection remains a significant cause of morbidity and mortality in children and adults undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Allogeneic HSCT recipients
Lehrnbecher, Thomas   +7 more
core   +1 more source

Patient reported outcomes in view of symptom experience of late effects and self-management of adult long-term survivors after allogeneic haematopoietic stem cell transplantation - a mixed methods study [PDF]

open access: yes, 2014
Even years after allogeneic stem cell transplantation, recipients face a continuing risk of developing serious late effects. Previous studies have focused on the pathophysiological understanding of late effects, as well as on treatment and disease ...
Kirsch, Monika
core   +1 more source

Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia

open access: yesScientific Reports, 2021
The evaluation of the somatic hypermutation of the clonotypic immunoglobulin heavy variable gene has become essential in the therapeutic management in chronic lymphocytic leukemia patients.
Crescenzio Francesco Minervini   +15 more
doaj   +1 more source

Hematopoietic stem cell transplantation

open access: yesStem Cells and Cloning: Advances and Applications, 2010
More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes.
Hatzimichael,Eleftheria, Tuthill,Mark
openaire   +5 more sources

Arrhythmia in Stem Cell Transplantation [PDF]

open access: yesCardiac Electrophysiology Clinics, 2015
Stem cell regenerative therapies hold promise for treating diseases across the spectrum of medicine. While significant progress has been made in the preclinical stages, the clinical application of cardiac cell therapy is limited by technical challenges.
Shone O, Almeida   +3 more
openaire   +2 more sources

Purification of Immature Neuronal Cells from Neural Stem Cell Progeny [PDF]

open access: yes
Large-scale proliferation and multi-lineage differentiation capabilities make neural stem cells (NSCs) a promising renewable source of cells for therapeutic applications.
Brent A Reynolds   +27 more
core   +2 more sources

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma [PDF]

open access: yes, 2004
We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10 ...
Mahendra, P   +37 more
core   +1 more source

Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation

open access: yesHaematologica
We compared long-term outcomes in 78 patients with steroid-refractory acute graft-versushost disease (SR-aGVHD) treated at the University Medical Center Hamburg, Germany between December 2015 and August 2022 who received either ruxolitinib alone (Ruxo ...
Iryna Lastovytska   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy